Veracyte, Inc. 12V.F Stock
Veracyte, Inc. Price Chart
Veracyte, Inc. 12V.F Financial and Trading Overview
| Veracyte, Inc. stock price | 20.4 EUR |
| Previous Close | 24.2 EUR |
| Open | 24.2 EUR |
| Bid | 24.2 EUR x 36100 |
| Ask | 24.4 EUR x 34700 |
| Day's Range | 24.2 - 24.2 EUR |
| 52 Week Range | 15.43 - 28.63 EUR |
| Volume | 200 EUR |
| Avg. Volume | 3 EUR |
| Market Cap | 1.85B EUR |
| Beta (5Y Monthly) | 1.379577 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.85 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.17 EUR |
12V.F Valuation Measures
| Enterprise Value | 1.63B EUR |
| Trailing P/E | N/A |
| Forward P/E | -47.45098 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.934353 |
| Price/Book (mrq) | 1.6200296 |
| Enterprise Value/Revenue | 5.245 |
| Enterprise Value/EBITDA | -274.708 |
Trading Information
Veracyte, Inc. Stock Price History
| Beta (5Y Monthly) | 1.379577 |
| 52-Week Change | 55.05% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 28.63 EUR |
| 52 Week Low | 15.43 EUR |
| 50-Day Moving Average | 21.47 EUR |
| 200-Day Moving Average | 21.71 EUR |
12V.F Share Statistics
| Avg. Volume (3 month) | 3 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 72.42M |
| Float | 72.04M |
| Short Ratio | N/A |
| % Held by Insiders | 1.15% |
| % Held by Institutions | 105.45% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -9.70% |
| Operating Margin (ttm) | -10.27% |
| Gross Margin | 65.38% |
| EBITDA Margin | -1.90% |
Management Effectiveness
| Return on Assets (ttm) | -1.71% |
| Return on Equity (ttm) | -2.78% |
Income Statement
| Revenue (ttm) | 311.18M EUR |
| Revenue Per Share (ttm) | 4.34 EUR |
| Quarterly Revenue Growth (yoy) | 21.60% |
| Gross Profit (ttm) | 194.95M EUR |
| EBITDA | -5941000 EUR |
| Net Income Avi to Common (ttm) | -30190000 EUR |
| Diluted EPS (ttm) | -0.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 177.89M EUR |
| Total Cash Per Share (mrq) | 2.46 EUR |
| Total Debt (mrq) | 13.99M EUR |
| Total Debt/Equity (mrq) | 1.29 EUR |
| Current Ratio (mrq) | 4.492 |
| Book Value Per Share (mrq) | 14.938 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 14.24M EUR |
| Levered Free Cash Flow (ttm) | 22.41M EUR |
Profile of Veracyte, Inc.
| Country | Germany |
| State | CA |
| City | South San Francisco |
| Address | 6000 Shoreline Court |
| ZIP | 94080 |
| Phone | 650 243 6300 |
| Website | https://www.veracyte.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 787 |
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Q&A For Veracyte, Inc. Stock
What is a current 12V.F stock price?
Veracyte, Inc. 12V.F stock price today per share is 20.4 EUR.
How to purchase Veracyte, Inc. stock?
You can buy 12V.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Veracyte, Inc.?
The stock symbol or ticker of Veracyte, Inc. is 12V.F.
Which industry does the Veracyte, Inc. company belong to?
The Veracyte, Inc. industry is Biotechnology.
How many shares does Veracyte, Inc. have in circulation?
The max supply of Veracyte, Inc. shares is 76.45M.
What is Veracyte, Inc. Price to Earnings Ratio (PE Ratio)?
Veracyte, Inc. PE Ratio is now.
What was Veracyte, Inc. earnings per share over the trailing 12 months (TTM)?
Veracyte, Inc. EPS is -0.85 EUR over the trailing 12 months.
Which sector does the Veracyte, Inc. company belong to?
The Veracyte, Inc. sector is Healthcare.